Silence Therapeutics aims to use the database to help identify new drug targets, as well as for patient recruitment and stratification in clinical trials.
NEW YORK (GenomeWeb) – Silence Therapeutics this month disclosed that it was ending its work with investigational sepsis drug Atu112 amid disappointing results in preclinical testing.
NEW YORK (GenomeWeb) – Silence Therapeutics this week announced the publication of preclinical data showing that its acute lung injury drug Atu111 could reduce the severity of sepsis-related illness and improve survival in mice.
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
NEW YORK (GenomeWeb) – Silence Therapeutics this week announced that it has completed patient recruitment for a Phase IIa trial of its siRNA-based cancer drug Atu027.
Silence Therapeutics this week announced that a collaborator is planning a phase Ib trial of the company's siRNA-based cancer drug Atu027 in combination with the chemotherapeutic agents cisplatin, 5-FU, and cetuximab for head and neck cancer.
Silence Therapeutics this week announced that its siRNA-based cancer drug Atu027 has progressed into the phase IIa portion of an ongoing phase Ib/IIa trial.
Silence Therapeutics this week announced that it has begun dosing patients in a phase Ib/IIa clinical trial of its cancer treatment Atu027 in combination with chemotherapy after having identified the drug’s maximum tolerated dose in a phase I study last year.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
